The primary objective of this study is to compare the
efficacy of early (presumptive vs diagnostic driven) Primary Therapy of
documented Invasive Aspergillosis (IA) in high-risk patients using Voriconazole
containing regiment in comparison with amphotericin B based Therapy. This is
a multicenter international study that aims at evaluating the global
experience, Far East (Japan), Middle East (Lebanon) and South America (Brazil).
All patients diagnosed with probable or definite invasive aspergillosis admitted to AUBMC.
The patient population to be included will consist of high–risk
patients with hematologic malignancy, HSCT and ICU critically ill patients with
invasive aspergillosis.
Inclusion criteria:
1- Age
range of patients: 12-86 years of age
2- Patients
with a proven or probable invasive aspergillosis (e.g., patients who have had a
CT scan of the chest done with either a documented positive culture for
aspergillosis or a documented positive galactomannan test in Bal or blood
whereby the appropriate antifungal therapy was started early (Empiric VS
diagnostic driven)
1. Subjects with other fungal infection such
as (mucormycosis, fusariosis, etc.)
2. Subjects with hematologic malignancy/
critically ill /HSCT who did not have a positive culture or biopsy positive for
aspergillosis (Possible IA)